Importantly, in adult brains, the expression of DAPK1 is restricted to the hippocampus, which is vulnerable to early and severe damage in the cortex [10,58], and this finding suggests that DAPK1 is a potential therapeutic target for AD treatment. The gene discussed is DAPK1; the disease is Alzheimer disease.